While miR-22 holds promise as a potential biomarker for response to hypomethylating agents due to its targeting of TET2, studies have not found a correlation between treatment response and miR-22 levels (31), suggesting the need for further investigation into its therapeutic implications in MDS. The gene discussed is TET2; the disease is myelodysplastic syndrome.